Takamatsu Y, Teshima T, Akashi K, Inaba S, Harada M, Niho Y
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Bone Marrow Transplant. 1994 Mar;13(3):325-7.
We describe a patient with acute myelogenous leukemia (AML) who received his second autologous blood stem cell transplantation (ABSCT) following a G-CSF-combined pre-transplant conditioning regimen. The patient underwent ABSCT during first remission but suffered a relapse 8 months later. After achieving second remission, he was prepared for his second ABSCT; recombinant human granulocyte colony-stimulating factor (rhG-CSF) was administered in combination with Ara C, in addition to the same conditioning regimen as that used before the first ABSCT. There was no increase in regimen-related toxicity after this second G-CSF-combined conditioning regimen when compared with that observed after the first ABSCT. To date, the patient's second remission following the second ABSCT has lasted 26 months, which has exceeded that following the first ABSCT. The G-CSF-combined pretransplant conditioning regimen for ABSCT may be effective in the treatment of high-risk AML by increasing the chemosensitivity of the residual leukemic cells.
我们描述了一名急性髓性白血病（AML）患者，该患者在接受粒细胞集落刺激因子（G-CSF）联合预处理方案后接受了第二次自体造血干细胞移植（ABSCT）。患者在首次缓解期接受了ABSCT，但8个月后复发。在达到第二次缓解后，他准备接受第二次ABSCT；除了与第一次ABSCT前相同的预处理方案外，还联合使用重组人粒细胞集落刺激因子（rhG-CSF）和阿糖胞苷（Ara C）。与第一次ABSCT后观察到的情况相比，第二次G-CSF联合预处理方案后与方案相关的毒性没有增加。迄今为止，患者第二次ABSCT后的第二次缓解期已持续26个月，超过了第一次ABSCT后的缓解期。用于ABSCT的G-CSF联合移植前预处理方案可能通过增加残留白血病细胞的化疗敏感性而有效治疗高危AML。
